JonesResearch says the Alabama Supreme Court ruling this week that frozen embryos created through in vitro fertilization are “extrauterine children” and are protected under state law sets a precedent that could potentially impact the entire U.S. IVF industry. In light of this, the firm expects greater interest in IVF alternatives, including Femasys’ intratubal insemination device, FemaSeed. FemaSeed received FDA clearance in September 2023 and preparations for a commercial launch are underway, the analyst tells investors in a research note. JonesResearch thinks FemaSeed could address an unmet need in male factor infertility. It keeps a Buy rating on the shares with a $7 price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on FEMY:
- Femasys Welcomes New Chief Commercial Officer Mr. Spector
- Femasys appoints Spector as CCO
- Femasys Inc. Advances Commercial Readiness with Appointment of Richard Spector to New Position of Chief Commercial Officer
- Femasys begins enrollment for FemBloc trial
- Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at UC Davis Medical Center, a Hub for Innovation and Groundbreaking Research in Health Care for Women
